Why I’d sell Woodford Patient Capital Trust plc today

G A Chester explains how Woodford Patient Capital Trust plc (LON:WPCT) has morphed into a much higher-risk investment than when it was launched.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I’ve reconsidered my position on master investor Neil Woodford’s Patient Capital Trust (LSE: WPCT), having reviewed its development since its launch in April 2015. The shares have performed poorly — they’re trading at 83p versus an IPO price of 100p — but there are more fundamental reasons why I now rate the trust a ‘sell’.

Prospectus

The trust issued a prospectus ahead of its launch and the following table summarises how Woodford expected the portfolio to look “one or two years from admission”:

Company type Characteristics Portfolio weighting
Mature Mid- and large-cap. Quoted companies. “Woodford’s high conviction blue-chip ideas.” c. 25%
Early growth “Typically quoted although may be unquoted companies.” c. 25%
Early stage “Likely to include both quoted and unquoted companies.” c. 50%

The trust appeared to offer a good balance between prudence and risk, with a decent chunk of the portfolio in liquid blue-chip stocks and even the second-tier early growth companies being “typically quoted.” While the weightings weren’t set in stone, there was a longstop on exposure to illiquid, unquoted companies, the prospectus declaring a maximum limit of 60% of net asset value (NAV) at the time of investment.

Also providing comfort on the risk front, the prospectus advised that while the trust was permitted to use gearing of up to 20% of NAV (at the time of borrowing), it “does not intend to deploy long-term gearing.”

Shaped up nicely

At the end of its first financial year (31 December 2015), it had shaped up nicely, being “substantially invested.” It held a small amount of cash and had no borrowings.

Mature companies, including FTSE 100 giants AstraZeneca, GlaxoSmithKline, Legal & General and Provident Financial, represented 30% of the portfolio. The early growth segment was at 23% and early stage at 46%. In terms of the balance of quoted and unquoted companies, the former had a weighting of 63% and the latter 36%.

A far higher risk proposition

However, the trust has morphed into a rather different animal to that envisaged in the prospectus. All its FTSE 100 holdings have been sold, the limit on unquoted companies has been increased from 60% to 80% and it’s dropped “does not intend to deploy long-term gearing” from its remit.

As of 30 November, I calculate that unquoted companies represented 78% of NAV and that Woodford had utilised £143m of a £150m overdraft facility, giving the trust gearing of 19%. The table below shows the top 10 holdings.

Company Status Market Weighting (%)
Prothena Quoted Nasdaq 11.8
Oxford Nanopore Unquoted n/a 9.3
Benevolent AI Unquoted n/a 7.1
Immunocore A Unquoted n/a 6.8
Purplebricks Quoted AIM 6.0
Proton Partners International Unquoted n/a 4.5
Autolus Unquoted n/a 4.4
Mereo Biopharma Quoted AIM 4.3
Atom Bank Unquoted n/a 4.2
Theravance Biopharma Quoted Nasdaq 3.9

The four quoted companies are all lossmaking and hardly seem to fit the prospectus mould of “Woodford’s high conviction blue-chip ideas.” Indeed, with the portfolio also stuffed to the hilt with unquoted companies (many of which require ongoing funding) and with the overdraft and gearing limit almost maxed out, the trust now looks a far higher-risk proposition than when it launched.

The shares currently trade at a discount of less than 10% to NAV. I believe the discount should be much wider and I rate the stock a ‘sell’.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

G A Chester has no position in any of the shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Bronze bull and bear figurines
Investing Articles

After the general election what might happen to the FTSE 100?

Our writer’s been looking at the manifestos of the three main political parties to try and understand how the general…

Read more »

Young Caucasian man making doubtful face at camera
Investing Articles

When will Shein hit the UK stock market and should I invest?

With Shein looking likely to list on the London stock market in 2024, this writer weighs up the case for…

Read more »

Investing Articles

Start supercharging passive income with REITs!

Are REITs the ultimate investment for boosting income generated from a portfolio? Zaven Boyrazian explores some of the most lucrative…

Read more »

Investing Articles

Should I buy more Rolls-Royce shares near 500p?

This investor is wondering whether to buy more Rolls-Royce shares this summer or to just stick with those he already…

Read more »

Investing Articles

After its big fall, is the National Grid share price dirt cheap now?

The National Grid share price fell sharply in reponse to new rights issue plans. But is it an even better…

Read more »

Aerial shot showing an aircraft shadow flying over an idyllic beach
Investing Articles

Starting in June, I’d invest £1,000 a month to aim for a £102,000 second income in retirement

This author highlights a less well-known FTSE 100 stock that could help his portfolio generate a very big second income…

Read more »

Investing Articles

Down 47% in 5 years, is the IAG share price due a bounce?

Many companies in the travel sector have seen fierce rallies since 2020. But with the IAG share price still down…

Read more »

Young black colleagues high-fiving each other at work
Investing Articles

Despite its drop, I reckon this is one of the best FTSE 100 stocks to buy and hold!

The FTSE 100 has been climbing in 2024 but this favourite of our writer's has been falling. Despite this, she’s…

Read more »